LymphedemaV1, France, Analysis, bibRecord, 000427

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

Identifieur interne : 000427 ( France/Analysis ); précédent : 000426; suivant : 000428

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

Auteurs : V. Diras [France, Niger] ; S. Limentani [États-Unis] ; G. Romieu [France] ; M. Tubiana-Hulin ; A. Lortholary [France] ; P. Kaufman [États-Unis] ; V. Girre [France] ; M. Besenval [France] ; V. Valero [États-Unis]

Source :

Annals of Oncology [ 0923-7534 ] ; 2008-04-01.

RBID : ISTEX:8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015

Abstract

Background: Treatment options are limited for patients with refractory metastatic breast cancer (MBC). Larotaxel (XRP9881) is a novel taxoid with preclinical activity against taxane-resistant breast cancer. The current phase II trial of larotaxel was conducted in women with taxane-treated MBC. Patients and methods: Patients were stratified by response to prior taxane therapy (resistant or nonresistant). Larotaxel 90 mg/m2 was administered as a 1-h infusion every 3 weeks. Patients were evaluated for tumor response every two cycles. A blinded external response review committee determined the overall response rate (ORR), duration of response (DOR), and time to progression (TtP) of the disease. Median survival time (MST) and safety were also evaluated. Results: One hundred and thirty patients were treated. In the nonresistant group, the ORR was 42%; median DOR 5.3 months; median TtP 5.4 months; and MST 22.6 months. In the resistant group, the ORR was 19%; median DOR 5.0 months; median TtP 1.6 months; and MST 9.8 months. The most common grade 3/4 adverse events were neutropenia (82%), fatigue (15%), diarrhea (12%), febrile neutropenia (9%), neutropenic infection (8%), and sensory neuropathy (7%). Conclusions: Larotaxel has good activity, manageable toxicity, and a favorable therapeutic index in women with taxane-pretreated MBC.

Url:

https://api.istex.fr/document/8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015/fulltext/pdf

DOI: 10.1093/annonc/mdn060

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 004331
to stream Istex, to step Curation: 004331
to stream Istex, to step Checkpoint: 000F24
to stream Main, to step Merge: 006D74
to stream Main, to step Curation: 006C65
to stream Main, to step Exploration: 006C65
to stream France, to step Extraction: 000427

Links to Exploration step

ISTEX:8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy</title>
<author><name sortKey="Diras, V" sort="Diras, V" uniqKey="Diras V" first="V." last="Diras">V. Diras</name>
</author>
<author><name sortKey="Limentani, S" sort="Limentani, S" uniqKey="Limentani S" first="S." last="Limentani">S. Limentani</name>
</author>
<author><name sortKey="Romieu, G" sort="Romieu, G" uniqKey="Romieu G" first="G." last="Romieu">G. Romieu</name>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
</author>
<author><name sortKey="Lortholary, A" sort="Lortholary, A" uniqKey="Lortholary A" first="A." last="Lortholary">A. Lortholary</name>
</author>
<author><name sortKey="Kaufman, P" sort="Kaufman, P" uniqKey="Kaufman P" first="P." last="Kaufman">P. Kaufman</name>
</author>
<author><name sortKey="Girre, V" sort="Girre, V" uniqKey="Girre V" first="V." last="Girre">V. Girre</name>
</author>
<author><name sortKey="Besenval, M" sort="Besenval, M" uniqKey="Besenval M" first="M." last="Besenval">M. Besenval</name>
</author>
<author><name sortKey="Valero, V" sort="Valero, V" uniqKey="Valero V" first="V." last="Valero">V. Valero</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1093/annonc/mdn060</idno>
<idno type="url">https://api.istex.fr/document/8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004331</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004331</idno>
<idno type="wicri:Area/Istex/Curation">004331</idno>
<idno type="wicri:Area/Istex/Checkpoint">000F24</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F24</idno>
<idno type="wicri:doubleKey">0923-7534:2008:Diras V:phase:ii:multicenter</idno>
<idno type="wicri:Area/Main/Merge">006D74</idno>
<idno type="wicri:Area/Main/Curation">006C65</idno>
<idno type="wicri:Area/Main/Exploration">006C65</idno>
<idno type="wicri:Area/France/Extraction">000427</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy</title>
<author><name sortKey="Diras, V" sort="Diras, V" uniqKey="Diras V" first="V." last="Diras">V. Diras</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Institut Curie, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Niger</country>
</affiliation>
</author>
<author><name sortKey="Limentani, S" sort="Limentani, S" uniqKey="Limentani S" first="S." last="Limentani">S. Limentani</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Carolinas Hematology-Oncology Associates, Charlotte, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Romieu, G" sort="Romieu, G" uniqKey="Romieu G" first="G." last="Romieu">G. Romieu</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Montpellier</settlement>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
<wicri:orgArea>Centre Val d'Aurelle</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
<affiliation><wicri:noCountry code="subField">Cloud</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lortholary, A" sort="Lortholary, A" uniqKey="Lortholary A" first="A." last="Lortholary">A. Lortholary</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Centre Catherine de Sienne, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kaufman, P" sort="Kaufman, P" uniqKey="Kaufman P" first="P." last="Kaufman">P. Kaufman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hematology/Oncology, Dartmouth/Hitchcock Medical Center, Lebanon, NH</wicri:regionArea>
<placeName><region type="state">New Hampshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Girre, V" sort="Girre, V" uniqKey="Girre V" first="V." last="Girre">V. Girre</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Institut Curie, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Besenval, M" sort="Besenval, M" uniqKey="Besenval M" first="M." last="Besenval">M. Besenval</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi-aventis, Bagneux</wicri:regionArea>
<wicri:noRegion>Bagneux</wicri:noRegion>
<wicri:noRegion>Bagneux</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Valero, V" sort="Valero, V" uniqKey="Valero V" first="V." last="Valero">V. Valero</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2008-04-01">2008-04-01</date>
<biblScope unit="volume">19</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1255">1255</biblScope>
<biblScope unit="page" to="1260">1260</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: Treatment options are limited for patients with refractory metastatic breast cancer (MBC). Larotaxel (XRP9881) is a novel taxoid with preclinical activity against taxane-resistant breast cancer. The current phase II trial of larotaxel was conducted in women with taxane-treated MBC. Patients and methods: Patients were stratified by response to prior taxane therapy (resistant or nonresistant). Larotaxel 90 mg/m2 was administered as a 1-h infusion every 3 weeks. Patients were evaluated for tumor response every two cycles. A blinded external response review committee determined the overall response rate (ORR), duration of response (DOR), and time to progression (TtP) of the disease. Median survival time (MST) and safety were also evaluated. Results: One hundred and thirty patients were treated. In the nonresistant group, the ORR was 42%; median DOR 5.3 months; median TtP 5.4 months; and MST 22.6 months. In the resistant group, the ORR was 19%; median DOR 5.0 months; median TtP 1.6 months; and MST 9.8 months. The most common grade 3/4 adverse events were neutropenia (82%), fatigue (15%), diarrhea (12%), febrile neutropenia (9%), neutropenic infection (8%), and sensory neuropathy (7%). Conclusions: Larotaxel has good activity, manageable toxicity, and a favorable therapeutic index in women with taxane-pretreated MBC.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Niger</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Languedoc-Roussillon</li>
<li>New Hampshire</li>
<li>Occitanie (région administrative)</li>
<li>Pays de la Loire</li>
<li>Texas</li>
<li>Île-de-France</li>
</region>
<settlement><li>Montpellier</li>
<li>Nantes</li>
<li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Diras, V" sort="Diras, V" uniqKey="Diras V" first="V." last="Diras">V. Diras</name>
</region>
<name sortKey="Besenval, M" sort="Besenval, M" uniqKey="Besenval M" first="M." last="Besenval">M. Besenval</name>
<name sortKey="Girre, V" sort="Girre, V" uniqKey="Girre V" first="V." last="Girre">V. Girre</name>
<name sortKey="Lortholary, A" sort="Lortholary, A" uniqKey="Lortholary A" first="A." last="Lortholary">A. Lortholary</name>
<name sortKey="Romieu, G" sort="Romieu, G" uniqKey="Romieu G" first="G." last="Romieu">G. Romieu</name>
</country>
<country name="Niger"><noRegion><name sortKey="Diras, V" sort="Diras, V" uniqKey="Diras V" first="V." last="Diras">V. Diras</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Limentani, S" sort="Limentani, S" uniqKey="Limentani S" first="S." last="Limentani">S. Limentani</name>
</region>
<name sortKey="Kaufman, P" sort="Kaufman, P" uniqKey="Kaufman P" first="P." last="Kaufman">P. Kaufman</name>
<name sortKey="Valero, V" sort="Valero, V" uniqKey="Valero V" first="V." last="Valero">V. Valero</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000427 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000427 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:8EB2E4D831E1D3CD5DE2EDB9051FDC60FFD0D015
   |texte=   Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri